Bayer Aktiengesellschaft

Bayer Pharma Aktiengesellschaft

Anja Buchmueller

Pierre Wasnaire

Peter Kolkhof

Carsten Schmeck

Klemens Lustig

Hanna Tinel

Axel Kretschmer

Elisabeth Pook

Heiko Schirmer

Chantal Fuerstner

Thomas Neubauer

Matthias Beat Wittwer

Thomas Mondritzki

Hana Cernecka

Karoline Droebner

Ursula Krenz

Marie-Pierre Collin

Marie-Pierre Collin-Kroepelin

Norbert Witowski

Guillaume Levilain

Robert Fricke

The present invention relates to prodrugs of 3-({3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl ]-4,5-dihydro-1H-1,2,4-triazol-1-yl}methyl)-1-[3-(trifluoromethyl)-pyridin-2-yl ]-1H-1,2,4-triazole-5-carboxamide, 3-({3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl ]-4,5-dihydro-1H-1,2,4-triazol-1-yl}methyl)-1-[2-(trifluoromethyl)-phenyl]-1H-1,2,4-triazole-5-carboxamide and 3-({3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl ]-4,5-dihydro-1H-1,2,4-triazol-1-yl}methyl)-1-(3-chloropyridin-2-yl)-1H-1,2,4-triazole-5-carboxamide, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of renal and cardiovascular diseases.

Prodrugs of substituted triazole derivatives and uses thereof

The present invention relates to novel 5-(carboxamide)-1-pyridinyl-1,2,4-triazole derivatives, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of renal and cardiovascular diseases.

Amide-substituted pyridinyltriazole derivatives and uses thereof

Growing community of inventors

Essen, Germany

Anja Buchmueller